SEC Form 4 · accession 0001179110-18-004009
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew M Gosling
Officer — SVP, General Counsel
Period of report
Mar 7, 2018
Accepted (ET)
Mar 9, 2018 · 7:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 7, 2018 | S | 45,519 | $6.58 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sold, in part, in accordance with divorce agreement.
- F2This price represents the average selling price (within a range of $6.48-$6.72) of the shares of common stock of Depomed, Inc. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares at each price within the range set forth in this footnote.